CHOC Children's Researcher Detail - William G Loudon, MD, PhD

CHOC Docs

Share |

William G Loudon, MD, PhD

Dr. Loudon has staff privileges at CHOC & CHOC at Mission

Location:
Orange, CA

Specialty:
Surgery, Neurological

Research Focus:
Molecular characterization and novel therapeutic approaches for CNS malignancy, cancer stem cell biology, and regenerative medicine

Published Works:

Jump to list

Office and Contact Information

West Coast Pediatric Neurosurgical Associates
1010 W La Veta Ave
#710
Orange, CA 92868
phone: (714) 835-2724
fax: (714) 835-2752
map & directions

Physician / Researcher Bio

Dr. Loudon received his medical degree from University of Texas at Houston and his Ph.D. in Cancer Biology from University of Texas, M.D. Anderson Cancer Center. Dr. Loudon performed his pediatric neurosurgical residency at Medical College of Virginia and his post-doctoral fellowship at Massey Cancer Institute/ Medical College of Virginia. Dr. Loudon completed his pediatric neurosurgery fellowship at University of Pennsylvania/Children's Hospital of Philadelphia. Dr. Loudon's expertise is in brain tumors and currently works with the CHOC Neuroscience and CHOC Cancer Institute in the development of the brain tumor program.

Research

Dr. Loudon is dedicated to the advancement of pediatric neuroscience. His past and present research has included studies investigating molecular characterization and novel therapeutic approaches for CNS malignancy, cancer stem cell biology, and regenerative medicine. He also has a patent pending on novel ex vivo 3-dimensional culture system for stem cell research.

As part of Dr. Loudon’s role on the CHOC concussion team, he is doing clinical research into the diagnosis and treatment of pediatric concussion and head injury.

Education

Fellowship
Pediatric neurosurgery fellowship at University of Pennsylvania/Children's Hospital of Philadelphia
Residency
Pediatric neurosurgical residency at Medical College of Virginia
Medical School
University of Texas at Houston

Board Certifications

Neurological Surgery

Honors and Awards

Orange County Medical Association’s Physicians of Excellence 2010-2012

Not a Moment to Spare
CHOC Children's Annual Report: FY 2010
The CHOC Children’s Pediatric Intensive Care Unit (PICU) was immediately alerted when paramedics brought an unconscious boy into the Hoag Hospital Newport Beach Emergency Department. At CHOC, pediatri...

Little Emily
Making a Mark: October 2008
Everything about this two-year-old girl?s life seems perfectly normal, other than the fact that it?s taking place at Children?s Hospital of Orange County (CHOC)...

Pursuing A Cure For Cancer
Physician Connection: Fall 2006
CHOC neurosurgeon William Loudon, M.D., Ph.D., has come to realize that with all the current clinical therapies available, only some of his brain tumor patients will be completely cancer-free after...

Helmets Are Cheap, Effective - And Required By Law
Kid's Health (Archive): Fall 2005
It's a sight CHOC neurosurgeon William Loudon, M.D., always hates to see: kids riding on scooters, rollerblades and skateboards without helmets....

More than 80 CHOC Children's Doctors Named "Physicians of Excellence"
January 03, 2012
More than 80 CHOC Children's physicians, including specialists and pediatricians, are named "Physicians of Excellence" by the Orange County Medical Association....

More than 60 CHOC Children’s Doctors Named “Physicians of Excellence”
January 04, 2011
More than 60 CHOC Children’s physicians, including specialists and pediatricians, are featured as "Physicians of Excellence" in the January 2011 issue of Orange Coast magazine. The "Physicians of Exc...

More than 50 CHOC Children's Doctors Named "Physicians of Excellence"
January 04, 2010
The Orange County Medical Association names more than 50 CHOC doctors "Physicians of Excellence."...

Published Works

Li SC, Han YP, Dethlefs BA, Loudon WG. Therapeutic window, a critical developmental stage for stem cell therapies. Curr Stem Cell Res Ther. 2010 Dec 1;5(4):297-3.

Li SC, Tachiki LM, Luo J, Dethlefs BA, Chen Z, Loudon WG. A biological global positioning system: considerations for tracking stem cell behaviors in the whole body. Stem Cell Rev. 2010 Jun;6(2):317-33. Review.

Li SC, Wang L, Jiang H, Acevedo J, Chang AC, Loudon WG. Stem cell engineering for treatment of heart diseases: potentials and challenges. Cell Biol Int. 2009 Mar;33(3):255-67. Epub 2008 Dec 3. Review.

Li SC, Loudon WG. A novel and generalizable organotypic slice platform to evaluate stem cell potential for targeting pediatric brain tumors. Cancer Cell International 8:9, 2008.

Mathews MS, Loudon WG, Muhonen MG, Sundine MJ. Historical Vignette: Vault reduction cranioplasty for extreme hydrocephalic macrocephaly. Journal of Neurosurgery (4 Suppl Pediatrics) 107:332-337, 2007. Also see Editorial 330-331.

Sundine MJ, Wirt GA, Brenner KA, Loudon WG. Cranial Vault Reduction Cranioplasty in Children with Hydrocephalic Macrocephaly . Journal of Craniofacial Surgery. 17(4):645-655, July 2006.

Brenner KA, Loudon WG, Sundine MJ. Acquired coronal craniosynostosis. J. Craniofac. Surg. 17:561-567, 2006.

Middelhof CA, WG Loudon, MD Muhonen, C Xavier, CS, Greene CS Jr.. Improved survival in central nervous system aspergillosis: a series of immunocompromised children with leukemia undergoing stereotactic resection of aspergillomas. Report of four cases. J Neurosurg. 2005 Oct;103(4 Suppl):374-8.

Loudon, WG, Sutton, LN. Childhood Malignant Gliomas. Contemporary Neurosurgery 22;19:1-9, 2000.

Broaddus WC, Liu Y, Loudon WG, Valerie K, Schmidt-Ulrich RK, Fillmore HL: Enhanced Radiosensitivity of Malignant Glioma Cells after Adenoviral p53 Transduction. J. Neurosurgery 91:997-1004, 1999.

Prabhu SS, Broaddus WC, Gillies GT, Loudon WG, Chen Z-J: Distribution of Macromolecular Dyes in Brain using Positive Pressure Infusion: A Model for Direct Controlled Delivery of Therapeutic Agents. Surgical Neurology, 50:367-75, 1998.

Broaddus WC, Chen ZJ, Prabhu SS, Loudon WG, Gillies GT, Phillips LL, Fillmore H: Antiproliferative effect of c-myc antisense phosphorothioate oligodeoxynucleotides in malignant glioma cells. Neurosurgery, 41(4):908-915, 1997.

Fujiwara T, Loudon WG, Grimm EA: Clones derived from Natural Killer cells are susceptible to lysis by human Interleukin-2-Activated killer cells. Lymphokine and Cytokine Res, 12(1):45-49, 1993.

Loudon WG, Hager-Loudon K, Saya H, Braoddus WC: Molecular probing of stereotactic biopsies as a potential means for the diagnosis and study of brain neoplasms. Human Gene Ther. 3(5 abstr. 20): 612, 1992.

List J, Moser RP, Steur M, Loudon WG, Blacklock JB, Grimm EA: Cytokine responses to intraventricular injection of interleukin-2 into patients with leptomeningeal carcinomatosis: Rapid induction of tumor necrosis factor-a, interleukin 1b, interleukin 6, g-interferon, and soluble interleukin 2 receptor (Mr 55,000 protein). Cancer Res. 52:1123-1128, 1992.

Grimm EA, Brunner JM, Carinhas J, Koeppen JA, Loudon WG, Owen-Schaub LB, Steck PA, Moser RP: Characterization of IL-2 initiated versus OKT-3 initiated human tumor infiltrating lymphocytes from glioblastoma multiforme: growth characteristics, cytolytic activity, and cell phenotype. Cancer Immunol Immunother, 32:391-399, 1991.

Grimm EA, Moser RP, Blacklock JB, Loudon WG, Carinhas J: Interleukin-2 and cytotoxic lymphocyte therapy of primary and metastatic brain tumors. IN: Pathophysiology of the Blood-Brain Barrier, BB Johansson, Ch Owmann, H Widner (eds), Elsevier Press, Amsterdam, pp 527-538, 1990.

Grimm EA, Owen-Schaub LB, Loudon WG, Yagita M: Lymphokine-activated killer cells: Induction and function. Ann NY Acad Sci, 532:480-481, 1988.

Loudon WG, Grimm EA: Biochemical dissection of human target cell surface determinants: relationship between tumor N-linked glycoproteins and LAK susceptibility. Ann NY Acad Sci, 532:472-474, 1988.

George RE, Loudon WG, Moser RP, Brunner JM, Steck PA, Grimm EA: In vitro cytolysis of primitive neuroectodermal tumors of the posterior fossa (medulloblastoma) by lymphokine-activated killer cells. J Neurosurg, 69:403-409, 1988.

Schaub LB, Loudon WG, Yagita M, Grimm EA: Functional differentiation of human lymphokine activated killing (LAK) is distinct from expansion and involves dissimilar Il-2 receptors. Cell Immunol, 111:235-246, 1988.

Loudon WG, Abraham SR, Schaub LB, Hemstreet GP, DeBault LE: Identification and selection of LAK effectors and novel recycling intermediates by unique light-scatter properties. Cancer Res, 48:2184-2192, 1988.

Yagita M, Loudon WG, Grimm EA: The toxic effect of lysosomotropic agent, L-leucine methyl ester, and its condensation product L-leucyl methyl-ester on NK, LAK, and CTL. J Cell Biochem, 10B:95, 1986.